Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Nuformix plc
NFXNuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom. Address: 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Analytics
Objectif de Cours de WallStreet
772.58 GBXRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés NFX
Analyse des dividendes NFX
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes NFX
Valorisation des titres NFX
financières NFX
Résultats | 2019 | Dynamique |